7/105 sources · 3 publishersUpdated Nov 10, 20:36 UTC
NeurAxis reports 150% Q3 revenue growth, wider loss and FDA clearance for IB‑Stim
NeurAxis announced third‑quarter 2026 results showing revenue roughly $2 million, up about 150% year over year, while net loss expanded to roughly $6.5 million. The company received FDA clearance for its IB‑Stim therapy and added coverage from major health insurers as well as a Veterans Affairs contract. Gross margin rose to 86.6% and cash on hand stood at $4.5 million after a $1.7 million ATM draw.
Why it matters
The firm said cash‑flow breakeven depends on sustaining the revenue growth. The widened loss reflects one‑time stock‑compensation charges and higher operating expenses, highlighting near‑term cash‑burn concerns.
Key facts
- 1Q3 2026 revenue was reported as $2.0 million. tradingview.com
- 2Q3 2026 revenue was reported as $2.03 million. tradingview.com
- 3Q3 2026 net loss was $6.54 million. rttnews.com
- 4Gross margin expanded to 86.6%. tradingview.com
- 5Cash on hand at September 30, 2026 was $4.5 million. tradingview.com
- 6The company withdrew $1.7 million from its at‑the‑market facility in early Q4. rttnews.com
Open questions
- Q3 revenue figure differs between $2.0 million and $2.03 million; material 3 reports $5.5 million, creating a conflict.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.